Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 3 art units • 5 examiners • 0 of 6 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (50%) |
| Double-patenting + other | 1 (17%) |
| Multi-statute (no §101) | 2 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAHMANI, NILOOFAR | 2 | 77.6% | -3.1% |
| JOHNSON, CHRISTOPHER LINDSAY | 1 | 48.4% | +80.0% |
| MCDOWELL, BRIAN E | 1 | 74.1% | +30.7% |
| ISMAIL, REHANA | 1 | 77.9% | +31.8% |
| CHANDRAKUMAR, NIZAL S | 1 | 72.7% | +18.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18709055 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH CENTRAL HYPOVENTILATION | RAHMANI, NILOOFAR | — |
| 18571847 | 5-HT2C AGONIST FOR USE IN TREATING CONDITIONS ASSOCIATED WITH CENTRAL HYPOVENTILATION | MCDOWELL, BRIAN E | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18708616 | METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA | JOHNSON, CHRISTOPHER LINDSAY | — |
| 18571847 | 5-HT2C AGONIST FOR USE IN TREATING CONDITIONS ASSOCIATED WITH CENTRAL HYPOVENTILATION | MCDOWELL, BRIAN E | — |
| 18548604 | COMBINATION OF REBOXETINE AND A MUSCARINIC RECEPTOR ANTAGONIST (MRA) FOR USE IN TREATING SLEEP APNEA | ISMAIL, REHANA | — |
| 18271716 | METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA | CHANDRAKUMAR, NIZAL S | — |
| Art Unit | Apps |
|---|---|
| 1625 | 2 |
| 1624 | 1 |
| 1691 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18709055 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH CENTRAL HYPOVENTILATION | RAHMANI, NILOOFAR | — | §102§112 | Non-Final OA | — | Pending | May 10, 2024 |
| 18708616 | METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA | JOHNSON, CHRISTOPHER LINDSAY | — | §103 | Non-Final OA | — | Pending | May 09, 2024 |
| 18571847 | 5-HT2C AGONIST FOR USE IN TREATING CONDITIONS ASSOCIATED WITH CENTRAL HYPOVENTILATION | MCDOWELL, BRIAN E | 1624 | §102§112 | Non-Final OA | — | Pending | Dec 19, 2023 |
| 18570673 | NOREPINEPHRINE REUPTAKE INHIBITORS FOR TREATING SLEEP APNEA | RAHMANI, NILOOFAR | 1691 | §103 | Final Rejection | — | Pending | Dec 15, 2023 |
| 18548604 | COMBINATION OF REBOXETINE AND A MUSCARINIC RECEPTOR ANTAGONIST (MRA) FOR USE IN TREATING SLEEP APNEA | ISMAIL, REHANA | 1625 | §102§103DPOther | Non-Final OA | — | Pending | Sep 01, 2023 |
| 18271716 | METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA | CHANDRAKUMAR, NIZAL S | 1625 | §103Other | Final Rejection | — | Pending | Jul 11, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial